盈康生命(300143.SZ)：上半年扣非淨利潤3176.75萬元 同比降25.17%
格隆匯8月23日丨盈康生命(300143.SZ)披露2019年半年度報告，報告期內公司實現營業收入2.55億元，同比增長1.52%；歸屬於上市公司股東的淨利潤2360.76萬元，同比下降48.13%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤3176.75萬元，同比下降25.17%；基本每股收益0.04元，加權平均淨資產收益率1.15%。
2019年上半年，公司圍繞年初制定的發展戰略和經營計劃，繼續加大醫療器械的研發投入及醫療服務的產業佈局，致力於打造全球首選物聯網“一站式”腫瘤綜合醫療服務平台，以“提供高端放療設備和優質醫療服務雙管齊下、協同發展”為經營戰略，以提高國產放療設備質量安全、為人民健康權益負責為企業願景，致力於服務腫瘤醫療全產業鏈。
2019年3月，公司控股股東變更為青島盈康醫療投資有限公司，實際控制人變更為海爾集團公司。公司將藉助股東優勢，圍繞公司戰略目標，進一步提升公司的綜合競爭力，為全體股東創造更大的價值。目前公司整體的戰略規劃和業務導向非常明確。
醫療器械方面：(1)以“INFINI”頭刀代表立體定向放射治療尖端水平的產品為核心，繼續保持國內市場佔有率第一的行業領先地位；
(2)積極拓展銷售渠道，實現發達國家及一帶一路國家出口銷售，契合“一帶一路”倡議；
(3)持續推進新型醫療設備的研發進程，實現臨牀驗證及拿到市場銷售許可；
(4)引進Protom質子治療設備，實現質子治療設備的國產化研發、生產、銷售，打造高端腫瘤放療設備的創新引領者；
(5)加強研發隊伍的建設，通過培育和引入高端研發人才提升公司整體的研發水平。同時公司將進一步加強與高等院校、研究所、醫學專家、國外高技術企業交流與合作，通過自主研發、技術合作等多種手段，保證公司研發能力的不斷提升。
醫療服務方面：(1)公司將通過打造區域中心旗艦醫院的模式，通過中心旗艦醫院資源的共享、上下聯動，發揮協同效應，並以西南、華東、華中、東北區域為先導，逐步實現全國性的腫瘤醫療服務網絡平台的搭建；
(2)同時公司將通過“內生式增長和外延式併購”的方式，不斷完善腫瘤專科醫院的佈局，包括建設質子旗艦中心醫院、腫瘤治療中心旗艦醫院、區域衞星醫院、合作中心等，打造國內領先的腫瘤治療產業良性持續發展平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
